Lok Sabha Question No. 1131 (UNSTARRED), answered on 2016-07-22
Subject: Annual Spending on Diabetes
Ministry: HEALTH AND FAMILY WELFARE
Asked by: BHAGWANTH KHUBA

## GOVERNMENT OF INDIA MINISTRY OF HEALTH AND FAMILY WELFARE DEPARTMENT OF HEALTH AND FAMILY WELFARE

## LOK SABHA UNSTARRED QUESTION NO. 1131 TO BE ANSWERED ON 2 2 ND JULY, 2016

## ANNUAL SPENDING ON D IABETES

## 1131. SHRI BHAGWANTH KHUBA:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether the annual spending of our country on diabetes is Rs. 1.5 lakh crore and it raises 30% per annum, which is five times the budgetary allocations on health sector;
- (b) if so, the details thereof;
- (c)  whether  the  Government  proposes to  implement  a  pilot  project  or  awareness p ogramme among the people of both urban and rural areas, if so, the details thereof;
- (d) whether the Insulin used in India is mostly imported and unaffordable by the common man ; and
- (e) if so, the details thereof and the steps taken to make available low - cost insulin in the country?

## ANSWER THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI FAGGAN SINGH KULASTE)

- (a) to (e) :  As per an article published in the newspaper, the annual spending of India on treatment is Rs.1.5 lakh crore, rising by 30% per annum and is 4.7 times the centres all on health sector.  However, as reported by Indian Council of Med ical Research (ICMR), it is difficult to put a figure on annual spending of our country on Diabetes. ICMR also reported that one  research  paper  suggested  that  estimated  cost  of  Diabetes  care  in  India  woul approximately 18,000 crores.

Department of Pha rmaceuticals has informed that as per Pharmatrac database of May, 2016 available with National Pharmaceutical Pricing Authority (NPPA), total Moving Annu Turnover (MAT) value of all pharmaceutical Stock Keeping Units (SKUs) is R.99475.9 crore out of wh ich MAT value of anti - diabetic medicines is Rs.8198.8 crores.

While Health is a State subject, to supplement the efforts of the State Government Government of India has launched National Programme for Prevention and Control of Cance Diabetes, Car diovascular Diseases and Stroke (NPCDCS) for interventions up to District le under the National Health Mission. NPCDCS has focus on awareness generation for behaviou and life - style changes, screening and early diagnosis of persons with high level of ri sk factors and their referral to higher facilities for appropriate management. Operational Guidelines for implementing population level screening for diabetes, hypertension & common cancer viz. breast  and  cervix  have  been  released  to  the  State  Gover nments.    These  guidelines  include screening  for  risk  factors  of  these  diseases.  Such  screening  will  generate  awareness factors of Diabetes among others.

ICMR  has  reported  that  Insulin  in  India  is  supplied  by  both  multinational  firms domesticfirms.  Several Indian Firms manufacture insulin in India and this is made  avail patients.  The cost of conventional insulins in India remains one of the cheapest anywher world  and  a  few  State  Governments  have  also  provisions  to  supply  it  f ree  of  cost  to  insulin requiring individuals. Newer insulin analogous are more expensive and are mai manufactured and marketed by multinational firms.

As reported by Department of Pharmaceuticals, Form III of Schedule II of DPCO, 201 captures infor mation regarding production or import of scheduled formulations.  It does not for segregated data on domestic production and import data.

National  List  of  Essential  Medicines  (NLEM)  contains  medicines  for  the  treatment common NCDs including diabetes.   As per National Pharmaceutical Pricing Authority thre Insulin  Injections  in  the  strength  of  40IU  /  ml  viz.,  Insulin  Injection  (Soluble),  In Acting (Lente/NPH Insulin) and Premix insulin 30:70 Injection are included in the schedul -Iof the Drugs Price Control Order(DPCO), 2013 and are under price control. The ceiling price DPCO 2013 is applicable to scheduled imported formulations also. Most public health facilities in the country provide those anti - diabetic medicines that are i ncluded in the NLEM free.